Navigation Links
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427

CHAPEL HILL, N.C., July 28, 2014 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today the positive results of a clinical trial demonstrating that CXL-1427, a novel potential treatment for acute decompensated heart failure (ADHF), was well tolerated in healthy volunteers. The company has now initiated dosing of hospitalized patients with decompensated heart failure in a Phase IIa clinical trial designed to further evaluate the drug's safety and tolerability as well as its dosing levels.

The Phase I clinical trial evaluated the safety and tolerability of 24- and 48-hour continuous intravenous infusions of CXL-1427 in 80 healthy volunteers. The trial's results showed not only that CXL-1427 was well tolerated with limited adverse events, but also that it is clearly hemodynamically active. Cardioxyl's ongoing Phase IIa study is a randomized, double-blinded, placebo-controlled, invasive hemodynamic study designed to evaluate the safety, tolerability and hemodynamic effects of 6-hour intravenous infusions of CXL-1427 in hospitalized patients with advanced heart failure. It is being conducted at up to 34 clinical sites globally and will enroll approximately 48 hospitalized patients.

"We are very encouraged by the results seen in the first clinical trial for CXL-1427," said ShiYin Foo, M.D., Ph.D., Cardioxyl's Chief Medical Officer, "and we are excited to have begun our next stage of clinical testing in advanced heart failure patients. Heart failure patients have few effective options, and the pre-clinical and clinical data for CXL-1427 suggest that this could be an important new therapy for patients with ADHF."  

Nitroxyl, the chemical name for HNO, has been studied for its potential as a treatment for heart failure. HNO dilates blood vessels and acts directly on the heart through a unique mechanism to safely enhance both systolic and diastolic function. Cardioxyl's proprietary platform of HNO technology has produced a number of candidate therapeutics for treating heart failure, including CXL-1427.

ADHF is the most severe form of heart failure and is the most common cause of hospitalization for patients over 65 years of age. A significant portion of the $39 billion spent annually to treat heart failure in the U.S. is directed at managing ADHF. Despite the prevalence and severity of the condition, the treatment options available for patients with ADHF remain limited.

About CXL-1427
CXL-1427 is a novel, improved second-generation prodrug that breaks down chemically to produce nitroxyl (HNO) and an inactive byproduct following intravenous administration. In extensive pre-clinical testing and in a Phase IIa human proof of concept study with Cardioxyl's first-generation prodrug, HNO was shown to produce a unique and very attractive hemodynamic profile. The novel combination of effects produced by Cardioxyl's HNO prodrugs distinguishes them from other therapies used in the treatment of congestive heart failure and provides a strong rationale for continuing the development of this important new class of drugs.

About Cardioxyl Pharmaceuticals
Cardioxyl Pharmaceuticals is focused on the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl (HNO) technology. The company's core HNO platform has generated several pre-clinical and clinical candidates. Cardioxyl is a privately held company financed by life science venture investors, including New Enterprise Associates, OrbiMed, Aurora Funds and Osage University Partners.

SOURCE Cardioxyl Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardioxyl Pharmaceuticals Raises $28 Million In Series B Financing Led By OrbiMed Advisors
2. Cardioxyl Pharmaceuticals Appoints Shi Yin Foo, M.D., Ph.D., As Chief Medical Officer
3. New Findings Published In Circulation: Heart Failure Show Potential Utility Of Cardioxyls HNO Donors As Novel Treatments For Heart Failure
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
10. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
11. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Post Your Comments:
(Date:10/13/2015)... 13, 2015  Yesterday Congresswoman Renee Ellmers ... manufacturing site located in Holly Springs, NC ... produced Flucelvax ® (Influenza Vaccine) using cell-culture technology, a ... start-up and is not reliant on chicken eggs. 1,2 ... influenza vaccines business of Novartis AG in the US, ...
(Date:10/12/2015)... -- Given the intricacy of the anatomy and ... an ophthalmic drug effectively to a specific ocular site. Several ... delivery. These include dilution of a drug by tears, clearance ... drug permeation issues with respect to the cornea, sclera and ... is lost due to the aforementioned barriers. --> ...
(Date:10/12/2015)... and CRANBURY, N.J. , Oct. ... LLP announces that a securities fraud class ... for the District of New Jersey.  The complaint alleges ... FOLD) violated the Securities Exchange Act of 1934 between ... materially false and misleading statements about Amicus Therapeutics, business ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... ... kind product that targets the unique health needs of new moms. Postnatal ... Pregnancy Association ( ), utilizes Nordic Naturals’ exclusive, new, ultra-concentrated omega-3 ...
(Date:10/13/2015)... ... 2015 , ... California Southern University has named Dr. Judith ... Doctor of Nursing Practice from the renowned Johns Hopkins University—comes to CalSouthern with ... McLeod’s long and successful nursing practice included a variety of patient care, education ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... Bill Saye as the newest professional to introduce the latest development, ThermiVa® temperature ... recognized as a leading professional in Obstetrics and Gynecology and a pioneer in ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... home furnishings and décor, today announced it closed on a $20.5 million funding ... will be used to support the Company’s continued rapid growth and expansion, broaden ...
(Date:10/13/2015)... ... 2015 , ... The Bill Howe Family of Companies is an award winning ... flood remediation services. Family-owned and operated for 35 years, they have maintained value, ethics ... plumber two years in a row from the Union Tribune Reader’s Poll, a Healthiest ...
Breaking Medicine News(10 mins):